branaplam
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Muscular Atrophy
Conditions
Spinal Muscular Atrophy
Trial Timeline
Apr 2, 2015 → Dec 29, 2022
NCT ID
NCT02268552About branaplam
branaplam is a phase 1/2 stage product being developed by Novartis for Spinal Muscular Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT02268552. Target conditions include Spinal Muscular Atrophy.
What happened to similar drugs?
7 of 20 similar drugs in Spinal Muscular Atrophy were approved
Approved (7) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02268552 | Phase 1/2 | Completed |
Competing Products
20 competing products in Spinal Muscular Atrophy